JPRN-UMIN000021099已完成未知
Prospective Cohort Study: Whether or Not Patients Benefit From Participation Itself in Randomized-controlled Trials 2 - Prospective Cohort Study: Whether or Not Patients Benefit From Participation Itself in Randomized-controlled Trials2 (SELECT BC ECO 2)
SELECT BC-CONFIRM executive committee0 个研究点目标入组 44 人开始时间: 2016年2月19日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 44
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •(i) Overexpression of HER2(Her2/neu, Erb B2), or the results of fluorescence in situ hybridization are positive. (ii) A past history of hypersensitivity to the protocoltreatment drugs or their solvents. (iii) The presence of other active cancers
研究者
相似试验
已完成
不适用
Prospective Cohort Study: Whether or Not Patients Benefit From Participation Itself in Randomized-controlled TrialsBreast CancerJPRN-UMIN000020645SELECT BC executive committee68
尚未招募
Unknown
A Prospective Observational Study of patients who switched from SGLT2 inhibitor tablets to luseogliflozin OD film formulation in terms of feeling, Efficacy and Safety of taking the medicine.Type 2 Diabetes MellitusJPRN-UMIN000050476Seino internal Medicine Clinic60
已完成
不适用
A nationwide prospective cohort study of patients with advanced chronic kidney disease (CKD G3b-G5) in JapaJPRN-UMIN000022145Department of Nephrology, Faculty of Medicine, University of Tsukuba2,249
尚未招募
不适用
Outcomes following a Multimodal Pain Protocol in Total Knee ArthroplastyTotal knee arthroplasty post operative pain and mobilitySurgery - Other surgeryMusculoskeletal - OsteoarthritisACTRN12612000343808Dr Gerald Yeo100
已完成
不适用
A prospective observational study of patients with advanced cancer for the evaluation of checkpoint inhibitor-associated cardiovascular immune-related adverse eventsAdvanced non-small-cell lung cancer and advanced gastric cancer which are indications for anti-cytotoxic T-lymphocyte-associated antigen-4, anti-programmed death-1, and anti-programmed death-ligand 1 antibodies.JPRN-UMIN000032729Frontline Immunotherapy Team, Sendai Kousei Hospital129